The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Open accessAbstract
BACKGROUND: Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis and limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition. METHODS: In this randomized, open-label, phase 3 trial, we assigned, in a 2:1 ratio, 361 patients with recurrent squamous-cell carcinoma of the head and neck whose disease had progressed within 6 months after platinum-based chemotherapy to receive nivolumab (at a dose of 3 mg per kilogram of body weight) every 2 weeks or standard, single-agent systemic therapy (methotrexate, docetaxel, or cetuximab). The primary end point was overall survival. Additional end points included progression-free survival, rate of objective response, safety, and patient-reported quality of life. RESULTS: The median overall survival was 7.5 months (95% confidence interval [CI], 5.5 to 9.1) in the nivolumab group versus 5.1 months (95% CI, 4.0 to 6.0) in the group that received standard therapy. Overall survival was significantly longer with nivolumab than with standard therapy (hazard ratio for death, 0.70; 97.73% CI, 0.51 to 0.96; P=0.01), and the estimates of the 1-year survival rate were approximately 19 percentage points higher with nivolumab than with standard therapy (36.0% vs. 16.6%). The median progression-free survival was 2.0 months (95% CI, 1.9 to 2.1) with nivolumab versus 2.3 months (95% CI, 1.9 to 3.1) with standard therapy (hazard ratio for disease progression or death, 0.89; 95% CI, 0.70 to 1.13; P=0.32). The rate of progression-free survival at 6 months was 19.7% with nivolumab versus 9.9% with standard therapy. The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group. Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group. Physical, role, and social functioning was stable in the nivolumab group, whereas it was meaningfully worse in the standard-therapy group. CONCLUSIONS: Among patients with platinum-refractory, recurrent squamous-cell carcinoma of the head and neck, treatment with nivolumab resulted in longer overall survival than treatment with standard, single-agent therapy. (Funded by Bristol-Myers Squibb; CheckMate 141 ClinicalTrials.gov number, NCT02105636 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [70]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Survival Analysis Techniques for Censored and Truncated Data
Rao, M. B., Klein, J. P., & Moeschberger, M. L. (1998) · Technometrics · doi:10.2307/1270658 · Cited by 3,617
Survival analysis using sas®: a practical guide
Allison, P. D. (1995) · International Linear Collider · Cited by 3,570
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Cooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,271
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,010
Tam, S., Yao, C., Amit, M., Gajera, M. V., Luo, X., Treistman, R., Khanna, A., Aashiq, M., Nagarajan, P., Bell, D., et al. (2019) · JAMA Otolaryngology - Head and Neck Surgery · doi:10.1001/jamaoto.2019.3751 · Cited by 69
Humbert, O., & Chardin, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.566297 · Cited by 79
Jiang, X., Xu, Y., Huang, M., Zhang, L., Su, M., Chen, X., & Lu, J. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.123 · Cited by 77
Otter, S., Chatterjee, J., Stewart, A., & Michael, A. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.003 · Cited by 78
MerTK as a therapeutic target in glioblastoma
Wu, J., Frady, L. N., Bash, R., Cohen, S. M., Schorzman, A. N., Su, Y.-T., Irvin, D., Zamboni, W. C., Wang, X., Frye, S. V., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox111 · Cited by 79
Modulation of antigen presenting cell functions during chronic HPV infection
Bashaw, A. A., Leggatt, G. R., Chandra, J., Tuong, Z. K., & Frazer, I. H. (2017) · Papillomavirus Research · doi:10.1016/j.pvr.2017.08.002 · Cited by 79
Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle
Cheng, W.-C., Tsui, Y., Ragusa, S., Koelzer, V. H., Mina, M., Franco, F., Laubli, H. P., Tschumi, B., Speiser, D. E., Romero, P. J., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0290-0 · Cited by 77
Adelstein, D. J., Ismaila, N., Ku, J. A., Burtness, B. A., Swiecicki, P. L., Mell, L. K., Beitler, J. J., Gross, N. D., Jones, C. U., Kaufman, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00441 · Cited by 76
Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma
Oosting, S., & Haddad, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00815 · Cited by 63
Self-citationLong Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Luo, Y., Yang, J., Yu, J., Liu, X., Yu, C., Hu, J., Shi, H., & Ma, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00048 · Cited by 74
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 79
Wang, Y., Zhang, X., Wang, Y., Zhao, W., Li, H., Zhang, L., Li, X., Zhang, T., Zhang, H., Huang, H., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.004 · Cited by 76
de Vries, H. M., Rafael, T. S., Gil-Jimenez, A., de Feijter, J. M., Bekers, E. M., van der Laan, E., López‐Yurda, M., Hooijberg, E., Broeks, A., Peters, D. D. G. C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02894 · Cited by 78
PD-1 regulation in immune homeostasis and immunotherapy
Gao, M., Shi, J., Xiao, X., Yao, Y., Chen, X., Wang, B., & Zhang, J. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216726 · Cited by 85
Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management
Prieux‐Klotz, C., Dior, M., Damotte, D., Dréanic, J., Brieau, B., Brézault, C., Abitbol, V., Chaussade, S., & Coriat, R. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0495-4 · Cited by 76
mTOR co-targeting strategies for head and neck cancer therapy
Wang, Z., Valera, J. L. C., Zhao, X., Chen, Q., & Gutkind, J. S. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9688-7 · Cited by 79
Signoretti, S., Flaifel, A., Chen, Y., & Reuter, V. E. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2259 · Cited by 76
Role of Immunotherapy in Head and Neck Cancer
Ling, D. C., Bakkenist, C. J., Ferris, R. L., & Clump, D. A. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.08.009 · Cited by 75
Self-citationOmarini, C., Guaitoli, G., Pipitone, S., Moscetti, L. I., Cortesi, L., Cascinu, S., & Piacentini, F. (2018) · Cancer Management and Research · doi:10.2147/cmar.s146658 · Cited by 75
Current Concepts in Chemotherapy for Head and Neck Cancer
Sindhu, S. K., & Bauman, J. E. (2018) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2018.09.003 · Cited by 75
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 77
Histone Deacetylase Inhibition Sensitizes PD1 Blockade–Resistant B-cell Lymphomas
Wang, X., Waschke, B. C., Woolaver, R. A., Chen, Z., Zhang, G., Piscopio, A. D., Liu, X., & Wang, J. H. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0875 · Cited by 77
Hyperthermia and immunotherapy: clinical opportunities
Hurwitz, M. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1653499 · Cited by 67
Rischin, D., Gil-Martín, M., González-Martı́n, A., Braña, I., Hou, J. Y., Cho, D., Falchook, G. S., Formenti, S. C., Jabbour, S. K., Moore, K. N., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.08.026 · Cited by 75
Therapeutic applications of herbal/synthetic/bio-drug in oral cancer: An update
Mosaddad, S. A., Beigi, K., Doroodizadeh, T., Haghnegahdar, M., Golfeshan, F., Ranjbar, R., & Tebyanian, H. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173657 · Cited by 75
Haring, C. T., Bhambhani, C., Brummel, C. V., Jewell, B. M., Bellile, E. L., Neal, M. E. H., Sandford, E., Spengler, R. M., Bhangale, A. D., Spector, M. E., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27992 · Cited by 75
Self-citationManagement of elderly patients with locoregionally confined head and neck cancer
Porceddu, S. V., & Haddad, R. I. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30229-2 · Cited by 75
Self-citationMaxwell, R., Luksik, A. S., Garzón-Muvdi, T., Hung, A. L., Kim, E. S., Wu, A., Xia, Y., Belcaid, Z., Gorelick, N. L., Choi, J. H., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1500108 · Cited by 79
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
Product review on the Anti-PD-L1 antibody atezolizumab
Shah, N. J., Kelly, W., Liu, S. V., Choquette, K., & Spira, A. I. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1403694 · Cited by 77
Nivolumab for the treatment of colorectal cancer
Smith, K. M., & Desai, J. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1480942 · Cited by 73
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
Meyers, D. E., Bryan, P., Banerji, S. O., & Morris, D. G. (2018) · Current Oncology · doi:10.3747/co.25.3976 · Cited by 74
Wu, J., Gensheimer, M. F., Zhang, N., Guo, M., Liang, R., Zhang, C., Fischbein, N. J., Pollom, E. L., Beadle, B. M., Le, Q., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230037 · Cited by 73
Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies
Sakakida, T., Ishikawa, T., Chihara, Y., Harita, S., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02214-8 · Cited by 73
ten Persigehl, T., Lennartz, S., & Schwartz, L. H. (2020) · Cancer Imaging · doi:10.1186/s40644-019-0281-x · Cited by 74
Bigelow, E. O., Seiwert, T., & Fakhry, C. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104652 · Cited by 65
Future Challenges in Cancer Resistance to Immunotherapy
van Elsas, M. J., van Hall, T., & van der Burg, S. H. (2020) · Cancers · doi:10.3390/cancers12040935 · Cited by 76
Patin, E. C., Dillon, M. T., Nenclares, P., Grove, L., Soliman, H., Leslie, I., Northcote, D., Bozhanova, G., Crespo-Rodriguez, E., Baldock, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004306 · Cited by 72
Self-citationCorrelates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 76
Kang, S.-H., Keam, B., Ahn, Y.-O., Park, H.-R., Kim, M., Kim, T. M., Kim, D.-W., & Heo, D. S. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1515057 · Cited by 72
Ma, H., Yang, W., Zhang, L., Liu, S., Zhao, M., Zhou, G., Wang, L., Jin, S., Zhang, Z., & Hu, J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0352-y · Cited by 79
Le, Q., Colevas, A. D., O’Sullivan, B., Lee, A. W. M., Lee, N. Y., Ma, B. B. Y., Siu, L. L., Waldron, J. N., Lim, C. M., Riaz, N., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz044 · Cited by 76
Self-citationJohnson, M. L., Braiteh, F., Grilley‐Olson, J. E., Chou, J., Davda, J. P., Forgie, A. J., Li, R., Jacobs, I. A., Kazazi, F., & Hu‐Lieskovan, S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0836 · Cited by 74
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy
Perri, F., Ionna, F., Longo, F., Scarpati, G. D. V., Angelis, C. D., Ottaiano, A., Botti, G., & Caponigro, F. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.11.008 · Cited by 73
Tumor microenvironment and immune-related therapies of head and neck squamous cell carcinoma
Qin, Y., Zheng, X., Gao, W., Wang, B., & Wu, Y. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.01.011 · Cited by 76
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
Oral leukoplakia remains a challenging condition
Villa, A., & Sonis, S. T. (2018) · Oral Diseases · doi:10.1111/odi.12781 · Cited by 73
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Next generation immune-checkpoints for cancer therapy
Donini, C., D’Ambrosio, L., Grignani, G., Aglietta, M., & Sangiolo, D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.02.79 · Cited by 74
Immune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 73
Al-Samadi, A., Poor, B., Tuomainen, K., Liu, V., Hyytiäinen, A., Sulymanova, I., Mesimaki, K., Wilkman, T., Mäkitie, A., Saavalainen, P., et al. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111508 · Cited by 63
The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer
Hofmann, L., Ludwig, S., Vahl, J. M., Brunner, C., Hoffmann, T. K., & Theodoraki, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114072 · Cited by 76
Designation Products: Boron Neutron Capture Therapy for Head and Neck Carcinoma
Kanno, H., Nagata, H., Ishiguro, A., Tsuzuranuki, S., Nakano, S., Nonaka, T., Kiyohara, K., Kimura, T., Sugawara, A., Okazaki, Y., et al. (2021) · The Oncologist · doi:10.1002/onco.13805 · Cited by 72
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 75
Cao, M., Shi, E., Wang, H., Mao, L., Wu, Q., Li, X., Liang, Y., Yang, X., Wang, Y., & Li, C. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s377816 · Cited by 72
Betanzos, C. M., Lee, H., Ericsson, P. I. G., Balko, J. M., Johnson, D. B., Zimmerman, L. J., & Liebler, D. C. (2017) · Molecular & Cellular Proteomics · doi:10.1074/mcp.ra117.000037 · Cited by 73
Outh-Gauer, S., Alt, M., Tourneau, C. L., Augustin, J., Broudin, C., Gasne, C., Denize, T., Mirghani, H., Fabre, E., Ménard, M., et al. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.008 · Cited by 73
Kreimer, A. R., Shiels, M. S., Fakhry, C., Johansson, M., Pawlita, M., Brennan, P., Hildesheim, A., & Waterboer, T. (2018) · Cancer · doi:10.1002/cncr.31256 · Cited by 72
Miyauchi, S., Sanders, P. D., Guram, K., Kim, S. S., Paolini, F., Venuti, A., Cohen, E. E. W., Gutkind, J. S., Califano, J. A., & Sharabi, A. B. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1771 · Cited by 73
Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71
Immunotherapy in head and neck cancer: aiming at EXTREME precision
Szturz, P., & Vermorken, J. B. (2017) · BMC Medicine · doi:10.1186/s12916-017-0879-4 · Cited by 73
Gyawali, B., Hey, S. P., & Kesselheim, A. S. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0416 · Cited by 73
Reck, M., Brahmer, J. R., Bennett, B., Taylor, F. C., Penrod, J. R., DeRosa, M., Dastani, H. B., Spigel, D. R., & Gralla, R. J. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.005 · Cited by 71
de Vicente, J. C., Rodríguez‐Santamarta, T., Rodrigo, J. P., Blanco‐Lorenzo, V., Allonca, E., & Garcia-Pedrero, J. M. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-0779 · Cited by 71
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 72
Liu, L., Lim, M. A., Jung, S., Oh, C., Won, H.-R., Jin, Y., Piao, Y., Kim, H. J., Chang, J. W., & Koo, B. S. (2021) · Phytomedicine · doi:10.1016/j.phymed.2021.153758 · Cited by 76
Kim, C. M., Lee, J. B., Shin, S. J., Ahn, J. B., Lee, M., & Kim, H. S. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100577 · Cited by 77
Bins, S., Basak, E. A., Bouazzaoui, S. E., Koolen, S. L. W., Hoop, E. O., van der Leest, C. H., van der Veldt, A. A. M., Sleijfer, S., Debets, R., van Schaik, R. H. N., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0074-1 · Cited by 70
Immune checkpoint inhibitors: new strategies to checkmate cancer
Wilson, R., Evans, T. R. J., Fraser, A. R., & Nibbs, R. J. B. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13081 · Cited by 72
Perrinjaquet, C., Desbaillets, N., & Hottinger, A. F. (2019) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000686 · Cited by 70
Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?
Lemiale, V., Meert, A., Vincent, F., Darmon, M., Bauer, P. R., de Louw, A. V., & Azoulay, É. (2019) · Annals of Intensive Care · doi:10.1186/s13613-019-0487-x · Cited by 73
Shimoji, K., Masuda, T., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Nakashima, T., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.22906 · Cited by 70
Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
Kanno, Y., Chen, C.-Y., Lee, H.-L., Chiou, J.-F., & Chen, Y.-J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640392 · Cited by 80
The Renaissance of Cyclin Dependent Kinase Inhibitors
Ettl, T., Schulz, D., & Bauer, R. J. (2022) · Cancers · doi:10.3390/cancers14020293 · Cited by 71
Mody, K., Jain, P., El-Refai, S. M., Azad, N. S., Zabransky, D. J., Baretti, M., Shroff, R. T., Kelley, R. K., El-Khoueiry, A. B., Hockenberry, A. J., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00510 · Cited by 71
Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity
Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., Picasso, V., Massari, F., & Gori, S. (2017) · Tumori Journal · doi:10.5301/tj.5000625 · Cited by 70
Hoesli, R. C., Birkeland, A. C., Rosko, A. J., Issa, M., Chow, K. L., Michmerhuizen, N. L., Mann, J. E., Chinn, S. B., Shuman, A. G., Prince, M. E., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.12.003 · Cited by 70
Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers
Inthagard, J., Edwards, J., & Roseweir, A. K. (2019) · Clinical Science · doi:10.1042/cs20181003 · Cited by 70
Hanna, G. J., Liu, H., Jones, R. E., Bacay, A. F., Lizotte, P. H., Ivanova, E. V., Bittinger, M. A., Cavanaugh, M. E., Rode, A. J., Schoenfeld, J. D., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.02.005 · Cited by 70
Self-citationCancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
Kidney Complications of Immune Checkpoint Inhibitors: A Review
Shingarev, R. A., & Glezerman, I. G. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.03.433 · Cited by 72
Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
Magnes, T., Wagner, S. M., Kiem, D., Weiß, L., Rinnerthaler, G., Greil, R., & Melchardt, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094981 · Cited by 74
Hamada, N., Maeda, A., Takase‐Minegishi, K., Kirino, Y., Sugiyama, Y., Namkoong, H., Horita, N., Yoshimi, R., Nakajima, H., & YCU irAE Working Group (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803410 · Cited by 71
Kao, H., Liao, B.-C., Huang, Y., Huang, H., Chen, C., Chen, T., Hong, Y.-J., Chan, C.-Y., Chia, J., & Hong, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3025 · Cited by 70
Ghosh, S., Shah, P. A., & Johnson, F. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147889 · Cited by 70
Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A. M., Sikic, B. I., Rahma, O. E., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005147 · Cited by 71
Mao, L., Xiao, Y., Yang, Q.-C., Yang, S.-C., Yang, L.-L., & Sun, Z.-J. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105472 · Cited by 68
Perrone, F., Minari, R., Bersanelli, M., Bordi, P., Tiseo, M., Favari, E., Sabato, R., & Buti, S. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000321 · Cited by 68
Leem, G., Park, J., Jeon, M., Kim, E.-S., Kim, S. W., Lee, Y. J., Choi, S. J., Choi, B., Park, S., Jung, I., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001650 · Cited by 68
Kawazoe, A., Itahashi, K., Yamamoto, N., Kotani, D., Kuboki, Y., Taniguchi, H., Harano, K., Naito, Y., Suzuki, M., Fukutani, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1929 · Cited by 71
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 73
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 75
Elias, A. W., Kasi, P. M., Stauffer, J. A., Thiel, D. D., Colibaseanu, D., Mody, K., Joseph, R. W., & Bagaria, S. P. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00121 · Cited by 68
New developments in the management of head and neck cancer – impact of pembrolizumab
Saleh, K., Eid, R., Haddad, F., Khalifé-Saleh, N., & Kourie, H. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s125059 · Cited by 62
Liang, F., Zhang, S., Wang, Q., & Li, W. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy075 · Cited by 70
Saba, N. F., Blumenschein, G. R., Guigay, J., Licitra, L. F., Fayette, J., Harrington, K. J., Kiyota, N., Gillison, M. L., Ferris, R. L., Jayaprakash, V., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.017 · Cited by 68
Self-citationPD-1 checkpoint inhibition: Toxicities and management
Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 68
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?
Masterson, L. M., Howard, J. E. F., Cruz, J. L. G., Jackson, C. C., Barnett, C. M. E., Overton, L., Liu, H. Y.-H., Ladwa, R., Simpson, F., McGrath, M., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32869 · Cited by 67
Yao, Y., Yan, Z., Lian, S., Wei, L., Chao Hui, Z. H. O. U., Feng, D., Zhang, Y., Yang, J., Li, M., & Chen, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000444 · Cited by 67
Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges
Almangush, A., Leivo, I. V. V., & Mäkitie, A. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.616629 · Cited by 67
Metadata
- Authors
- Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., Worden, F., Saba, N. F., Iglesias Docampo, L. C., Haddad, R., Rordorf, T., Kiyota, N., Tahara, M., Monga, M., Lynch, M., Geese, W. J., Kopit, J., Shaw, J. W., & Gillison, M. L.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-10
- Volume
- 375
- Issue
- 19
- Pages
- 1856-1867
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5564292
- OpenAlex
- W2529484692
- Cited by
- 5,101
- References
- 26
- Citations by year
- 2026: 358 · 2025: 461 · 2024: 500 · 2023: 490 · 2022: 574 · 2021: 687 · 2020: 617 · 2019: 543 · 2018: 486 · 2017: 358 · 2016: 17
- FWCI
- 452.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institute for Health and Care Research (NF-SI-0515-10101)
- Ono Pharmaceutical
- National Cancer Institute (P50CA097190, R01CA206517)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Head and Neck Cancer Studies
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Dermatology › Nonmelanoma Skin Cancer Studies
- Keywords
- nivolumab, PD-1 inhibitors, immune checkpoint inhibitors, platinum-refractory disease, overall survival, progression-free survival, objective response rate, quality of life, treatment-related adverse events, cetuximab, docetaxel, methotrexate, single-agent chemotherapy, metastatic head and neck cancer, immunotherapy
- MeSH terms
- Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Male, Neoplasm Recurrence, Local, Quality of Life, Survival Analysis, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
